Nurse-like cells control the activity of chronic lymphocytic leukemia b cells via galectin-1 by Croci Russo, Diego Omar et al.
Accepted Article Preview: Published ahead of advance online publication
Nurse-like cells control the activity of chronic lymphocytic
leukemia B cells via galectin-1
DO Croci, PE Morande, SD Dylon, M Borge, MA Toscano,
JC Stupirski, RF Bezares, JS Avalos, M Narbaitz, R
Gamberale, GA Rabinovich, M Giordano
Cite this article as: DO Croci, PE Morande, SD Dylon, M Borge, MA Toscano,
JC Stupirski, RF Bezares, JS Avalos, M Narbaitz, R Gamberale, GA Rabinovich,
M Giordano, Nurse-like cells control the activity of chronic lymphocytic leukemia
B cells via galectin-1, Leukemia accepted article preview 7 November 2012; doi:
10.1038/leu.2012.315.
This is a PDF ﬁle of an unedited peer-reviewed manuscript that has been accepted
for publication. NPG are providing this early version of the manuscript as a service
to our customers. The manuscript will undergo copyediting, typesetting and a proof
review before it is published in its ﬁnal form. Please note that during the production
process errors may be discovered which could affect the content, and all legal
disclaimers apply.
Accepted article preview online 7 November 2012
© 2012 Macmillan Publishers Limited. All rights reserved
 1
Nurse-like cells control the activity of chronic lymphocytic leukemia B 1 
cells via galectin-1 2 
Letter to the Editor 3 
 4 
Chronic lymphocytic leukemia (CLL) cells are preferentially activated in so-called 5 
proliferation centers frequently found in lymph nodes and bone marrow from CLL patients1. 6 
In these “privileged” sites leukemic cells establish close contact with a variety of cell types 7 
that provide long-term support for their survival and progression. In addition, CLL cells 8 
favor the establishment of immunosuppressive microenvironments by altering the cytokine 9 
milieu2. Galectin 1 (Gal1), an endogenous β-galactoside-binding lectin found at sites of 10 
inflammation and tumor growth, displays pro-survival activity on malignant cells as 11 
demonstrated for CD45RA(-) primary myeloma cells3. Moreover it controls tumor cell 12 
proliferation and invasiveness and plays key roles in tumor-immune escape by dampening T 13 
cell-mediated immunity4. In Hodgkin lymphoma Gal1 is over-expressed in Reed-Sternberg 14 
cells, is a predictive biomarker of disease progression and is responsible for creating the 15 
Th2/regulatory T cell–skewed microenvironment typical of this lymphoproliferative 16 
disease5. These unique characteristics of Gal1 prompted us to investigate its potential role in 17 
CLL biology. 18 
 19 
We first assessed the expression of Gal1 in peripheral blood and bone marrow 20 
samples from CLL patients using qRT-PCR, flow cytometry and immunohistochemistry. 21 
We found that monocytes in peripheral blood (Fig 1.A and B) and stromal and myeloid cells 22 
in bone marrow biopsies (Fig 1.C) are the main sources of Gal1. CLL cells do not express 23 
Gal1, but they are able to bind Gal1 in a dose-dependent manner (Fig 1.D). This effect was 24 
glycan-specific, as addition of the disaccharide lactose, but not sucrose inhibited binding of 25 
Gal1 to CLL cells (Fig 1.D).   26 
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In the presence of leukemic cells, monocytes from CLL patients can differentiate in 27 
vitro into large, adherent cells that protect the leukemic clone from spontaneous and drug-28 
induced apoptosis. These so-called nurse-like cells (NLC) reside in lymphoid tissues where 29 
they presumably deliver pro-survival and stimulating signals to CLL cells6. To determine 30 
whether Gal1 secreted by myeloid cells can influence leukemic B cells responses, we 31 
knocked down Gal1 synthesis in NLC. For this purpose, we differentiated NLC from 32 
peripheral blood CLL samples as previously described7, removed non-adherent cells (> 90% 33 
leukemic B cells) and transduced adherent NLC with retrovirus expressing Gal1-specific 34 
short hairpin RNA (shRNA-gal1) or a scrambled control shRNA (shRNA-scr) (Fig 1.E, F). 35 
After 6 h of incubation, transduced NLC were thoroughly washed and non-adherent cells 36 
were incorporated to the plates for further co-culture. Thereafter, we evaluated in the 37 
leukemic clone expression of the activation markers CD80, CD86 and CD25, production of 38 
IL-10 as a prototypical anti-inflammatory cytokine and synthesis of CCL3 and CCL4 as key 39 
chemokines responsible for the recruitment of monocytes and T lymphocytes to lymphoid 40 
tissues. We found that blockade of Gal1 in NLC impaired the expression of activation 41 
markers in CLL cells suggesting that the presence of endogenous Gal1 in myeloid cells is 42 
required for full stimulation of the leukemic clone (Suppl. Fig 1). Blockade of Gal1 also 43 
decreased mRNA and protein levels of IL-10 and mRNA levels of CCL3 in CLL cells, 44 
without affecting those of CCL4 (Fig 1.G, H). While previous reports showed that 45 
recombinant Gal1 induces the release of IL-10 from activated T lymphocytes and dendritic 46 
cells8, there is still no information on its effects on CCL3. Of note, both IL-10 and CCL3, 47 
are relevant in CLL pathogenesis as their serum concentrations are elevated in CLL 48 
patients9, 10 and, more importantly, they correlate with shorter time-to-first treatment (TTFT) 49 
and survival11.  50 
Since B-cell receptor (BCR) signaling plays a central role in the survival, 51 
proliferation and trafficking of CLL cells12, we evaluated whether Gal1 can modulate this 52 
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pathway. We found that, in the presence of Gal1, suboptimal concentrations of anti-IgM can 53 
fully activate the BCR signaling in CLL cells, as assessed by Syk and Erk1/2 54 
phosphorylation (Fig 1.I), indicating that Gal1 may decrease the threshold of BCR 55 
activation probably through the formation of lattices as previously suggested for the pre-56 
BCR synapse formation and other receptor-ligand systems4, 13. While these results suggest 57 
that Gal1 secreted by NLC may exert a direct effect on the leukemic clone, we also found 58 
that knocking down Gal1 diminished the expression of BAFF and APRIL in NLC (Fig 1.J). 59 
Although not evaluated in leukemic cells, BAFF is able to enhance CD86 and induce the 60 
secretion of IL-10 in resting B cells14. Hence, Gal1 secreted by NLC might directly or 61 
indirectly influence CLL activity through glycan-dependent binding to these cells and 62 
modulation of BCR signaling or through the control of BAFF and/or APRIL secretion.  63 
Next, we determined the concentration of Gal1 in plasma from 49 CLL samples and 64 
40 age-matched healthy donors. Clinical features of CLL patients are depicted in 65 
Supplementary Table 1. Plasma concentrations of Gal1 were significantly increased in CLL 66 
patients compared to healthy subjects (Fig. 2.A; p<0.0001). When we discriminated CLL 67 
patients in high and low risk groups according to the expression of CD38 and ZAP-70 on 68 
CLL cells, we observed a trend (although not statistically significant) to increased levels of 69 
Gal1 in plasma from patients expressing one or both prognostic markers compared to the 70 
double-negative group (Fig.2.B). Similarly, we observed that patients in Binet A staging had 71 
about half the concentration of Gal1 in plasma compared to patients in Binet C (208 vs 517 72 
ng/ml, n=25 vs 7). Finally, we analyzed the expression of Gal1 in bone marrow biopsies 73 
from patients with stable and progressive disease. We found both an increased number of 74 
cells expressing Gal1 and a higher expression of this lectin in bone marrow samples from 75 
patients with progressive disease (Fig. 2.C, E). In agreement with previous reports 15, we 76 
also observed increased numbers of CD68+ cells in samples from patients with progressive 77 
disease (Fig. 2D, E). These data indicate that Gal1 is associated with poor outcome in CLL.  78 
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Collectively, our findings suggest that Gal1 secreted by accompanying myeloid cells 79 
(i.e. NLC, macrophages and dendritic cells) contributes to stimulate the activity of CLL 80 
cells and may help to establish the appropriate microenvironmental conditions for leukemic 81 
progression. From a therapeutic standpoint, our study suggests that selective manipulation 82 
of Gal1 expression in NLC may be able to influence CLL differentiation and survival, a 83 
critical effect with implications in the design of novel anti-leukemic therapies. 84 
 85 
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Legends to Figures: 179 
 180 
Figure 1: Myeloid cell-derived Gal1 modulates CLL cell function and signaling. (A-D) 181 
Gal1 expression in peripheral blood and bone marrow from CLL patients and binding of 182 
Gal1 to leukemic B cells. (A) Gal1 expression was assessed in fixed and permeabilized 183 
PBMC from CLL patients by flow cytometry. B lymphocytes (> 98% CLL cells) and 184 
monocytes were discriminated by CD19 and CD14 expression. Results are shown as mean 185 
fluorescence intensity ratio (MFIR) (n=5). Left, representative histograms (Red: isotype 186 
control, Blue: Gal1) in CD19- or CD14-expressing cells. ** p<0.01. (B) mRNA levels of 187 
Gal1 in CD19+ or CD14+ cells from CLL patients. Data are the mean ± SD (n=9) *** 188 
p<0.001. RE: band intensity relative to actin. (C) Immunoperoxidase staining of Gal1 in 189 
CLL bone marrow aspirates. Strong Gal1 expression was detected in a minor fraction of 190 
cells associated with infiltrating lymphocytes, which correspond to CD68+ cells showing 191 
macrophage or dendritic cell-like morphology. (D) PBMC from CLL patients were 192 
incubated with increasing concentrations of biotin-conjugated Gal1 in the presence or 193 
absence of lactose 10 mM and washed before tagging with streptavidin-FITC. Viable 194 
leukemic cells were discriminated by forward-scatter gating and CD19 labeling and 195 
analyzed by flow cytometry. Results are shown as rMFI of Gal1 binding. Values are the 196 
mean ± SD from 9 CLL samples evaluated. rMFI (relative mean fluorescence intensity) = 197 
(MFI with Gal1 – MFI without Gal1) / MFI without Gal1. (E-I) Inhibition of Gal1 198 
expression in NLC affects leukemic B cell responses. In vitro differentiated NLC from CLL 199 
patients were infected with Gal1-specific shRNA (shRNA-Gal1) or scrambled control 200 
shRNA (shRNA-scr) and analyzed thereafter for Gal1 expression. (E) Western blot analysis 201 
and (F) mRNA levels of Gal1 in NLC following siRNA silencing (n=9), (** p<0.01; 202 
Student´s t-test). (G) mRNA expression of CCL3, CCL4 and IL-10 in CLL cells incubated 203 
for 72 h with transduced NLC. Results are the mean ± SD; n=9. (G) Secretion of IL-10 from 204 
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in CLL cells incubated for 72 h with transduced NLC. Results are the mean SD; n=8. (I) 205 
Analysis of BCR signaling in Gal1-treated CLL cells. Immunoblot of Syk and Erk1/2 206 
phosphorylation in cells incubated for 5 min with anti-IgM (0.1 μM), Gal1 (3 μM) or Gal1 + 207 
anti-IgM. Two representative out of seven experiments corresponding each to an individual 208 
patient are shown (left). (J) mRNA expression of BAFF and APRIL in transduced NLC at 209 
72 h of cell culture. Results are the mean ± SD; n=9. ** p<0.01.   210 
 211 
Figure 2: Expression of Gal1 in plasma and bone marrow samples from CLL patients. (A) 212 
Plasma levels of Gal1 in age-matched healthy donors and CLL patients. p<0.0001. (B) 213 
Plasma levels of Gal1 in CD38- ZAP70- (low risk) and CD38+ and/or ZAP70+ (high risk) 214 
CLL patients. (C-E) Gal1 expression in bone marrow samples from 6 stable and 7 215 
progressive CLL patients. (C) Semiquantitative analysis of Gal1 expression within CLL-216 
infiltrating areas from stable or progressive patients. n=13 p=0.012 (Mann Whitney U test). 217 
(D) Analysis of presence of CD68+ cells in CLL-infiltrating areas. n=11 p=0.008 (Mann 218 
Whitney U test).  (E) Representative images from stable or progressive CLL biopsies 219 
showing Gal1 (left) or CD68 (Right) expression are shown. 220 
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